| Date | Title | Description |
| 20.09.2024 | Joint acquisition of Immedica Pharma completed | Joint acquisition of Immedica Pharma completed
Fri, Sep 20, 2024 08:00 CET Report this content
Stockholm, September 20, 2024 – KKR, a leading global investment firm, and Impilo, a Nordic healthcare investment firm, have today announced the ... |
| 18.09.2024 | Immedica Pharma: A New Era in Rare Disease Treatment | Immedica Pharma is making waves in the pharmaceutical industry. With a focus on rare diseases, the company is poised for significant growth. Recent leadership changes and clinical advancements signal a promising future.
On September 17, 202... |
| 18.09.2024 | Immedica initiates a phase 3 pediatric study for Loargys® (pegzilarginase) in arginase 1 deficiency | Immedica initiates a phase 3 pediatric study for Loargys® (pegzilarginase) in arginase 1 deficiency
Wed, Sep 18, 2024 14:45 CET Report this content
Stockholm, September 18, 2024: Immedica announces today that the first subject has been dose... |
| 17.09.2024 | Immedica appoints Daniel Camardo as President of Immedica North America | Immedica appoints Daniel Camardo as President of Immedica North America
Tue, Sep 17, 2024 13:00 CET Report this content
Stockholm, September 17, 2024 – Immedica Pharma AB announces today the appointment of Daniel Camardo as President of Imm... |
| 09.09.2024 | Immedica expands into the U.S., establishes Chicago-based commercial business | Immedica expands into the U.S., establishes Chicago-based commercial business
Mon, Sep 09, 2024 12:00 CET Report this content
Stockholm, September 9, 2024 – Immedica Pharma AB, a global pharmaceutical company dedicated to addressing rare an... |
| 03.09.2024 | Immedica presents new data highlighting treatment benefits of Loargys® (pegzilarginase) in arginase 1 deficiency at the SSIEM congress | Immedica presents new data highlighting treatment benefits of Loargys® (pegzilarginase) in arginase 1 deficiency at the SSIEM congress
Tue, Sep 03, 2024 11:00 CET Report this content
Stockholm, September 3, 2024: Immedica announces today th... |
| 15.06.2024 | Immedica’s partner Actinium announces Iomab-B phase 3 SIERRA trial results in patients with TP53 mutation at the EHA 2024 Annual Congress | Immedica’s partner Actinium announces Iomab-B phase 3 SIERRA trial results in patients with TP53 mutation at the EHA 2024 Annual Congress
Sat, Jun 15, 2024 17:30 CET Report this content
Stockholm, June 15, 2024 - Immedica’s partner Actinium... |
| 26.04.2024 | Immedica announces publication of 2023 Business Review and Annual & Sustainability Report | Immedica announces publication of 2023 Business Review and Annual & Sustainability Report
Fri, Apr 26, 2024 13:15 CET Report this content
Stockholm, April 26, 2024 – Immedica is proud to announce the release of our Business Review and A... |
| 23.04.2024 | Leading global investment firm KKR and Nordic healthcare investment firm Impilo enters strategic partnership together with Immedica management | Leading global investment firm KKR and Nordic healthcare investment firm Impilo enters strategic partnership together with Immedica management
Tue, Apr 23, 2024 07:15 CET Report this content
Stockholm, April 23, 2024 –Investment funds manag... |
| 19.04.2024 | Immedica recognized as one of Sweden’s Best Workplaces 2024 by Great Place To Work® | Immedica recognized as one of Sweden’s Best Workplaces 2024 by Great Place To Work®
Fri, Apr 19, 2024 09:40 CET Report this content
Stockholm, April 19, 2024 – Immedica has made the list of Sveriges Bästa Arbetsplatser™ (Sweden's Best Workp... |
| 18.04.2024 | Immedica’s partner Actinium announces Iomab-B phase 3 SIERRA trial results in patients with a TP53 mutation presented in an oral presentation at the 50th EBMT annual meeting | Immedica’s partner Actinium announces Iomab-B phase 3 SIERRA trial results in patients with a TP53 mutation presented in an oral presentation at the 50th EBMT annual meeting
Thu, Apr 18, 2024 10:15 CET Report this content
Stockholm, April 1... |
| 21.03.2024 | Ravicti® (glycerol phenylbutyrate) approved by the Taiwan Food and Drug Administration (TFDA) for the treatment of Urea Cycle Disorders | Ravicti® (glycerol phenylbutyrate) approved by the Taiwan Food and Drug Administration (TFDA) for the treatment of Urea Cycle Disorders
Thu, Mar 21, 2024 12:15 CET Report this content
Stockholm, March 21, 2024 – Immedica and its partner Win... |
| 29.02.2024 | From anonymity to recognition: The challenge of underdiagnosis and misdiagnosis in rare diseases | From anonymity to recognition: The challenge of underdiagnosis and misdiagnosis in rare diseases
Thu, Feb 29, 2024 08:00 CET Report this content
As we highlight Rare Disease Day, it’s crucial to focus on the often-overlooked issue of underd... |
| 27.02.2024 | Immedica’s partner Actinium presented four abstracts of Iomab-B at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® | Immedica’s partner Actinium presented four abstracts of Iomab-B at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Tue, Feb 27, 2024 08:00 CET Report this content
Stockholm, February 27, 2024... |
| 22.12.2023 | Loargys® (pegzilarginase) approved in Great Britain for treatment of arginase 1 deficiency (ARG1-D) | Loargys® (pegzilarginase) approved in Great Britain for treatment of arginase 1 deficiency (ARG1-D)
Fri, Dec 22, 2023 10:15 CET Report this content
Stockholm, 21, 2023: Immedica today announces that the Medicines & Healthcare products R... |
| 21.12.2023 | Immedica intends to re-submit the BLA seeking approval of Loargys® (pegzilarginase) for treatment of arginase 1 deficiency (ARG1-D) in the US | Immedica intends to re-submit the BLA seeking approval of Loargys® (pegzilarginase) for treatment of arginase 1 deficiency (ARG1-D) in the US
Thu, Dec 21, 2023 11:00 CET Report this content
Stockholm, December 21, 2023: Immedica today annou... |
| 18.12.2023 | Loargys® (pegzilarginase) approved in the EU for treatment of arginase 1 deficiency (ARG1-D) | Loargys® (pegzilarginase) approved in the EU for treatment of arginase 1 deficiency (ARG1-D)
Mon, Dec 18, 2023 15:15 CET Report this content
Stockholm, December 18, 2023: Immedica today announces that the European Commission has granted mar... |
| 14.11.2023 | Immedica’s partner Actinium announces oral presentation at ASH annual meeting on Iomab-B outcomes data for TP53 gene mutation from the SIERRA trial | Immedica’s partner Actinium announces oral presentation at ASH annual meeting on Iomab-B outcomes data for TP53 gene mutation from the SIERRA trial
Tue, Nov 14, 2023 14:30 CET Report this content
Stockholm, November 14 , 2023 – Immedica’s p... |
| 20.10.2023 | Glycerol phenylbutyrate granted orphan drug designation for treatment of STXBP1 developmental and epileptic encephalopathy | Glycerol phenylbutyrate granted orphan drug designation for treatment of STXBP1 developmental and epileptic encephalopathy
Fri, Oct 20, 2023 10:00 CET Report this content
Stockholm, October 20, 2023 – Immedica today announces that the Europ... |
| 13.10.2023 | Loargys® (pegzilarginase) receives positive opinion by the CHMP for treatment of arginase 1 deficiency | Loargys® (pegzilarginase) receives positive opinion by the CHMP for treatment of arginase 1 deficiency
Fri, Oct 13, 2023 13:40 CET Report this content
Stockholm, October 13, 2023: Immedica today announces that the Committee for Medicinal Pr... |
| 29.09.2023 | Ravicti® (glycerol phenylbutyrate) approved by the National Administration of Drugs, Food and Medical Devices in Argentina for treatment of urea cycle disorders | Ravicti® (glycerol phenylbutyrate) approved by the National Administration of Drugs, Food and Medical Devices in Argentina for treatment of urea cycle disorders
Fri, Sep 29, 2023 09:30 CET Report this content
Stockholm, September 29, 2023 –... |
| 28.08.2023 | Immedica to present new pegzilarginase data at the SSIEM Annual Symposium 2023 | Immedica to present new pegzilarginase data at the SSIEM Annual Symposium 2023
Mon, Aug 28, 2023 14:00 CET Report this content
Stockholm, August 28, 2023 Immedica today announces the presentation of new data at the SSIEM (Society for the St... |
| 25.08.2023 | I131-apamistamab SIERRA abstracts accepted for oral and poster presentation at the European Association of Nuclear Medicine 2023 Congress | I131-apamistamab SIERRA abstracts accepted for oral and poster presentation at the European Association of Nuclear Medicine 2023 Congress
Fri, Aug 25, 2023 08:00 CET Report this content
Stockholm, August 25, 2023 – Immedica’s partner Actini... |
| 27.07.2023 | Immedica acquires global rights to pegzilarginase from Aeglea | Immedica acquires global rights to pegzilarginase from Aeglea
Thu, Jul 27, 2023 13:05 CET Report this content
Stockholm, July 27, 2023 – Immedica announces that it has signed an agreement to acquire the global rights to pegzilarginase and r... |
| 21.07.2023 | Zepzelca® (lurbinectedin) approved by the Ministry of Health in Oman for the treatment of metastatic Small Cell Lung Cancer | Zepzelca® (lurbinectedin) approved by the Ministry of Health in Oman for the treatment of metastatic Small Cell Lung Cancer
Fri, Jul 21, 2023 13:15 CET Report this content
Stockholm, July 21, 2023 – Immedica’s product Zepzelca® (lurbinected... |
| 21.06.2023 | Glycerol phenylbutyrate approved by the National Medical Products Administration in China for the treatment of Urea Cycle Disorders | Glycerol phenylbutyrate approved by the National Medical Products Administration in China for the treatment of Urea Cycle Disorders
Wed, Jun 21, 2023 07:30 CET Report this content
Stockholm, June 21, 2023 – Immedica’s partner Hongkong WinHe... |
| 15.05.2023 | Iomab-B SIERRA trial results accepted for oral presentation at the European Hematology Association 2023 Congress | Iomab-B SIERRA trial results accepted for oral presentation at the European Hematology Association 2023 Congress
Mon, May 15, 2023 11:19 CET Report this content
Stockholm, May 15 , 2023 – Immedica’s partner Actinium Pharmaceuticals, Inc. ha... |
| 26.04.2023 | Immedica publishes Business Review and Annual & Sustainability report 2022 | Immedica publishes Business Review and Annual & Sustainability report 2022
Wed, Apr 26, 2023 10:35 CET Report this content
Stockholm, April 26 , 2023 - Immedica has today published its Business review and Annual & Sustainability rep... |
| 21.04.2023 | Immedica’s partner OrphanPacific initiates phase 3 trial with glycerol phenylbutyrate for treatment of urea cycle disorders in Japan | Immedica’s partner OrphanPacific initiates phase 3 trial with glycerol phenylbutyrate for treatment of urea cycle disorders in Japan
Fri, Apr 21, 2023 14:15 CET Report this content
Stockholm, April 21 , 2023 - Immedica’s partner OrphanPacif... |
| 23.02.2023 | Positive results from the pivotal phase 3 SIERRA trial in patients with relapsed or refractory acute myeloid leukemia | Positive results from the pivotal phase 3 SIERRA trial in patients with relapsed or refractory acute myeloid leukemia
Thu, Feb 23, 2023 10:37 CET Report this content
Stockholm, February 23, 2023 - Immedica’s partner Actinium Pharmaceuticals... |
| 24.01.2023 | Helsinn and Immedica enter exclusive partnership for commercialization of cancer supportive care products in core European markets | Helsinn and Immedica enter exclusive partnership for commercialization of cancer supportive care products in core European markets
Tue, Jan 24, 2023 09:00 CET Report this content
LUGANO, Switzerland and STOCKHOLM, Sweden – January 24, 2023 ... |
| 01.09.2021 | Pharma Mar S A : PharmaMar announces the approval of Zepzelca® (lurbinectedin) for the treatment of metastatic Small Cell Lung Cancer in the United Arab Emirates | PharmaMar announces the approval of
Zepzelca® (lurbinectedin) for the treatment of
metastatic Small Cell Lung Cancer in the
United Arab Emirates
This approval is based on overall response rate and duration of response, demonstrated in the o... |
